Are you 21 or older?

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of fifteen amino acids — derived from a sequence found in human gastric juice, where the parent protein BPC (also called “bpc” or PL-10 in older literature) was originally isolated. The compound is frequently referred to as a “stable gastric pentadecapeptide” in the preclinical literature.

In its original description, BPC was characterised as a protein fragment with cytoprotective properties in the gastric lining. The 15-amino-acid derivative — BPC-157 — was developed as a synthetic, sequence-stable research compound and is the form sold for laboratory study.

BPC-157 has been investigated almost exclusively in preclinical models — rodent in vivo work, isolated cell systems, and ex vivo tissue preparations. No large, peer-reviewed human clinical trials of BPC-157 have been published in the indexed literature.

Mechanism of action

The mechanism literature for BPC-157 is broad and sometimes imprecise — partly because the compound interacts with several distinct signalling systems simultaneously, and partly because the early literature was published across Croatian, Hungarian, and other central-European venues that did not always describe methods to current reporting standards.

Across the available evidence, the most consistently reported mechanistic themes are:

• Vascular endothelial growth factor (VEGF) and angiogenesis — BPC-157 promotes the formation of new blood vessels in rodent models of ischemic injury and tendon transection.
• Nitric oxide (NO) system interaction — the compound appears to modulate endothelial nitric oxide synthase (eNOS) activity and counteract NO-system blockade.
• FGF and EGF signalling — fibroblast growth factor and epidermal growth factor receptor pathways, both involved in tissue repair cascades.
• Collagen and extracellular matrix synthesis — increased fibroblast outgrowth and collagen organisation in tendon and skin models.
• Cytoprotection in gastric and hepatic models — protection of gastric mucosa against NSAID, alcohol, and restraint-stress-induced lesions.

Angiogenesis & vascular effects

The strongest single thread in the BPC-157 literature is its effect on angiogenesis — the formation of new capillary networks from existing vasculature. Several preclinical studies have reported accelerated vessel formation in rat and mouse models of hind-limb ischemia, skin wounds, and tendon transection.

The proposed pathway involves VEGF receptor 2 (VEGFR2) signalling, with measurable increases in capillary density and perfusion in treated tissues versus controls. Whether this translates to clinically meaningful outcomes in human ischemic or wound-healing contexts is unknown.

The “angiogenesis” framing is sometimes borrowed to support claims about athletic recovery, soft-tissue repair, and post-surgical healing — none of which have been demonstrated in human trials of BPC-157.

Nitric oxide system interaction

A second recurring mechanism is BPC-157’s interaction with the L-arginine / NO pathway. Studies using NO synthase inhibitors (such as L-NAME) have reported that BPC-157 counteracts some of the inhibitory effects of NO blockade on vascular function and gastric cytoprotection.

The interpretation is that BPC-157 may act as a “NO system stabiliser” rather than a direct NO agonist — though the underlying mechanism remains incompletely characterised. This is one of the more speculative areas of the BPC-157 mechanism story.

Tendon, ligament & bone research

Tendon and ligament repair is one of the most active areas of BPC-157 preclinical research. Studies in rat Achilles tendon transection models have reported:

• Faster functional recovery of Achilles tendon after surgical transection.
• Improved biomechanical properties of the healed tendon (load-to-failure testing).
• Increased fibroblast outgrowth and collagen fibre organisation at the repair site.
• Counteraction of corticosteroid-induced healing impairment.

Comparable findings have been reported in medial collateral ligament and bone-fracture models. These results are promising but consistent with a fundamental limit of preclinical tendon research: rodent tendons heal more readily than human tendons, and the translation is unreliable.

Gastrointestinal research

The original BPC protein was identified in gastric juice, and BPC-157’s gastroprotective properties are among the most robustly replicated findings. Across multiple rodent studies, the compound has been shown to:

• Protect gastric mucosa against ethanol-, NSAID-, and restraint-stress-induced lesions.
• Accelerate the healing of pre-existing gastric ulcers in rat models.
• Reduce intestinal inflammation in models of inflammatory bowel disease.

These are credible findings in the preclinical context but, again, no human trials of BPC-157 for any gastrointestinal indication have been published in the peer-reviewed literature.

Limits of the evidence

Several limitations shape how the BPC-157 literature should be read:

• No human trials. The compound has not been studied in any large, peer-reviewed human clinical trial. The closest human data is anecdotal case-report material and uncontrolled clinical observations — neither of which constitutes clinical evidence.
• Concentration & formulation variability. Preclinical studies use widely varying doses, routes, and peptide formulations. Direct comparison between studies is difficult.
• Reporting quality. Earlier studies, particularly from the 1990s and 2000s, were published in venues with less rigorous reporting standards. Modern systematic reviews note frequent issues with randomisation, blinding, and statistical methods.
• Mechanism specificity. BPC-157 interacts with multiple signalling systems. The “primary mechanism” is contested, and the compound is sometimes described as pleiotropic.
• Off-label use. BPC-157 is sold “for research use only” and is increasingly used off-label in human populations despite no human safety or efficacy data.

Regulatory status

BPC-157 is not approved by the FDA, EMA, MHRA, or equivalent regulatory bodies for any human indication. The FDA has flagged BPC-157 as a bulk drug substance with potential safety concerns, and the compound is on the agency’s peptide watch-list. The U.S. Anti-Doping Agency classifies BPC-157 as a prohibited substance for athletes.

In the United States, BPC-157 is sold primarily as a “research peptide” not intended for human consumption. In Australia, BPC-157 has been a scheduled substance since 2017. The compound remains unscheduled in most other jurisdictions, but is increasingly subject to review as off-label use expands.